Related Experiment Video

Updated: Feb 11, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.7K

[Infarct-related cardiogenic shock : Prognosis and treatment]

R Prondzinsky1,2, H Lemm3, A Geppert4

  • 1Medizinische Klinik I, Carl-von-Basedow-Klinikum Saalekreis gGmbH, Weiße Mauer 52, 06217, Merseburg, Deutschland. r.prondzinsky@klinikum-merseburg.de.

Medizinische Klinik, Intensivmedizin Und Notfallmedizin
|May 4, 2018
PubMed

Insights

Early diagnosis and intervention, including percutaneous coronary intervention (PCI), improve survival for patients with ST segment elevation myocardial infarction (STEMI) and cardiogenic shock. Prompt cardiovascular support is crucial for recovery.

Area of Science:

  • Cardiology
  • Intensive Care Medicine

Background:

  • Cardiogenic shock complicates ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI) in 6-10% of cases.
  • Incidence is decreasing due to advancements in invasive diagnostics and therapy post-myocardial infarction.

Purpose of the Study:

  • To review current treatment strategies for cardiogenic shock complicating myocardial infarction.
  • To highlight the importance of early diagnosis and revascularization.
  • To discuss pharmacological and mechanical support options.

Main Methods:

  • Review of current literature on cardiogenic shock management.
  • Discussion of revascularization techniques like percutaneous coronary intervention (PCI).
  • Overview of pharmacological agents (dobutamine, norepinephrine, levosimendan) and mechanical support (Impella, ECMO).

Main Results:

  • Early PCI significantly improves survival rates in STEMI patients with cardiogenic shock.
  • Pharmacological support involves inotropes and vasopressors; levosimendan offers additional support.
  • Mechanical support systems like Impella and ECMO are vital, while IABP use has declined.
  • Most survivors experience minimal long-term cardiac impairment, indicating transient damage.

Conclusions:

  • Fast and effective cardiovascular supportive therapy is essential for cardiogenic shock survivors.
  • Prompt diagnosis and revascularization are key to improving outcomes.
  • A combination of pharmacological and mechanical support optimizes myocardial and organ perfusion.

Keywords:
CatecholaminesExtracorporeal membrane oxygenationMyocardial infarctionMyocardial revascularizationStents

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.1K
Ploidy Manipulation of Zebrafish Embryos with Heat Shock 2 Treatment11:19

Ploidy Manipulation of Zebrafish Embryos with Heat Shock 2 Treatment

Published on: December 16, 2016

10.4K

Related Concept Videos

Shock Waves01:16

Shock Waves

While deriving the Doppler formula for the observed frequency of a sound wave, it is assumed that the speed of sound in the medium is greater than the source's speed through it. When this condition is breached, a shock wave occurs.
When the source's speed approaches the speed of sound, constructive interference between successive wavefronts emitted by the source occurs immediately behind it. Initially, scientists believed that this constructive interference would result in such high...
2.6K
Blood Pressure Imbalances and Circulatory Shock01:24

Blood Pressure Imbalances and Circulatory Shock

Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
1.7K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
975